DNV3837: Clinical Trial News

DNV3837 From my news feed: #research #clinicaltrials news.

 The second part of the Phase II clinical trial of DNV3837 in Clostridioides difficile infections to be extended to Canada.

 In Phase II, everyone gets the treatment.

 DNV3837 is a narrow-spectrum, hybrid oxazolidinone-quinolone synthetic antibiotic targeting only Gram-positive bacteria.

 It is developed as a highly active first-line treatment targeting C. diff.

 It’s an IV antibiotic, so it’s good for people with severe diarrhea, for whom oral antibiotics may have trouble staying in the intestines long enough to kill off c-diff. It crosses the GI barrier and goes straight to where the bacteria are to specifically target it where it lives.

 Article contains a link to more info on the trials.

Leave a comment

Filed under C-Diff

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s